Vor Biopharma has done well to continue to advance its very own global phase 3 study using its dual BAFF/APRIL inhibitor ...
So nearly a massive result for Rob Edwards' traveling outfit after a late equaliser from Tolu Arokodare, but a brace of own ...
Hosted on MSN
The Amazing Image Stabiliser Inside Your Head: Understanding The Vestibulo-Ocular Reflex
Imagine you’re in a board room and quickly turn your head to see who’s speaking. Whether you’re playing sports, watching tennis at Wimbledon, or walking along a busy street, every time you move your ...
The Register on MSN
Australia bans teens from social media, but nobody thinks it'll really work
Still, the ban has reset expectations and may reduce harm, and that’s kind of enough Australia's ban on children under 16 ...
Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share. The gross proceeds from the offering are expected to be $100 million. In ...
Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...
You’re unlikely to open a medicine cabinet in the U.S. without seeing a bottle of Tylenol, the brand name of a pain reliever and fever reducer also sold generically as acetaminophen. A health care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback